Wong Hing C 4

What Happened
Wong Hing C, CEO of HCW Biologics (HCWB), purchased 23,210 shares on July 29, 2026 at $2.58 per share for a total of $59,998 in a private placement (transaction code P). The filing also states the reporting person is entitled to receive common warrants exercisable for up to 23,210 shares; issuance of those warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). The purchase was made directly from the issuer under a Securities Purchase Agreement dated July 29, 2026 and was claimed exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.

Key Details

• Transaction date and price: 2026-07-29, 23,210 shares at $2.58 each.
• Total purchase value: $59,998.
• Transaction type: P = Purchase (private placement from issuer under SPA).
• Warrants: entitlement to common warrants exercisable for up to 23,210 shares; issuance requires shareholder approval under Nasdaq Listing Rule 5635(d); if issued, warrants would be exercisable immediately and expire 5.5 years after issuance.
• Registration/exemption: Purchased pursuant to SPA and exempt from registration under Section 4(a)(2) and/or Rule 506(b).
• Shares owned after transaction: not disclosed in the Form 4.
• Filing timeliness: Form 4 filed 2026-07-31 reporting the 2026-07-29 transaction — appears timely (filed within the typical 2-business-day window).

Context
This was a direct purchase from the company (not an open-market buy). Purchases by executives can be interpreted by retail investors as a more informative signal than routine sales, but filings do not disclose the insider’s motives. The additional warrants are conditional on shareholder approval; until approved and issued, they are a potential future source of dilution.